Publications   Surgery Photos   No-Scalpel Vasectomy   Impotence   Laparoscopic Surgery   Dr. Whang's Blog   Transplant experience  

Date : 13-05-05 09:16     
Writer : HIFU    Views : 34,192
Astellas Bladder Treatment Wins U.S. Approval for Sale
Astellas Bladder Treatment Wins U.S. Approval for Sale
Posted on July 2, 2012

Astellas Pharma Inc. won approval 
for its overactive bladder treatment aimed at an estimated 33 
million Americans who suffer from the condition.

Dr. Whang Comments:
There are already 7 or more medications (anticholinergic medications) approved by the FDA for treatment of overactive bladder (OAB). There are several side effects of  the anticholinergic medications including dry mouth, constipation, sedation and urinary retention. In men with an enlarged prostate (BPH) and overactive bladder,  urinary retention ( inability to void) is a significant concern. This new medication (Myrbetriq) claims to have less risk of urinary retention. If true, it would be a great advantage for men with BPH and overactive bladder. It does have some significant side effects including increased heart rate and high blood pressure.   As a result, Myrbetriq isn’t recommended for use in those with severe uncontrolled high blood pressure, end-stage kidney disease or severe liver impairment.

Posted in Uncategorized 


Contact us | HOME |  matthew whang facebook  matthew whang youtube  matthew whang twitter 
ABOUT HIFU About HIFU |  Contact us |  Treatments |  Considering HIFU? |  FAQ |  Privacy Statement |  CURRICULUM VITAE |  HIFU VIDEO |  VIDEO | 
UROLOGY Publications |  Surgery Photos |  No-Scalpel Vasectomy |  Impotence |  Laparoscopic Surgery |  Dr. Whang's Blog |  Transplant experience | 
Dr. Matthew Whang Urology Group of New Jersey | 1001 Pleasant Valley Way, West Orange, NJ 07052 | Tel.: ( 973) 669-8448 I Fax: (973) 669- 9536
Copyright 2013. All right reserved. Dr. Matthew Whang